Center-Authored Papers

Filters: Author is Radich, Jerald  [Clear All Filters]
2017
Ailawadhi S, Akard LP, Miller CB, Jillella A, DeAngelo DJ, Ericson SG, Lin F, Warsi G, Radich J.  2017.  Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib.. Therapeutic advances in hematology. 8(1):3-12. Abstract
Radich J.  2017.  Understanding CML, 1 cell at a time.. Blood. 129(17):2339-2340.
Yeung CCS, Radich J.  2017.  Predicting Chemotherapy Resistance in AML.. Current hematologic malignancy reports. Abstract
2016
Egan D, Radich J.  2016.  Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL.. Best practice & research. Clinical haematology. 29(3):252-263. Abstract
Bansal A, Radich J.  2016.  Is cure for chronic myeloid leukemia possible in the tyrosine kinase inhibitors era? Current opinion in hematology. 23(2):115-20. Abstract
McDougall J, Ramsey SD, Radich J.  2016.  What Happens When Imatinib Goes Generic? Journal of the National Comprehensive Cancer Network : JNCCN. 14(2):128-31.
Radich J.  2016.  When to Consider Allogeneic Transplantation in CML.. Clinical lymphoma, myeloma & leukemia. 16 Suppl:S93-5. Abstract
Egan D, Radich J.  2016.  Monitoring Disease Burden in Chronic Myeloid Leukemia: Past, Present, and Future.. American journal of hematology. Abstract
Yeung CCS, Egan D, Radich J.  2016.  New Methodologies in the Molecular Monitoring of CML.. Current hematologic malignancy reports. 11(2):94-101. Abstract
2015
Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S.  2015.  The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.. Blood. 126(13):1551-1554. Abstract
Egan D, Radich J.  2015.  Prognosis and Molecular Monitoring in Chronic Myeloid Leukemia.. Clinical lymphoma, myeloma & leukemia. 15S:S109-S113. Abstract
Radich J.  2015.  Splicing up the classification of myelodysplasia.. Blood. 126(2):128-9.
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Kluibenschaedl M, Conrads-Frank A, Stenehjem D, Brixner D, Radich J et al..  2015.  Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.. Leukemia & lymphoma. :1-11. Abstract
Maxson JE, Abel ML, Wang J, Deng X, Reckel S, Luty SB, Sun H, Gorenstein J, Hughes SB, Bottomly D et al..  2015.  Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.. Cancer research. Abstract
Rochau U, Kluibenschaedl M, Stenehjem D, Kuan-Ling K, Radich J, Oderda G, Brixner D, Siebert U.  2015.  Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.. Leukemia research and treatment. 2015:982395. Abstract
Martinelli G, Oehler VG, Papayannidis C, Courtney R, Shaik NM, Zhang X, O'Connell A, McLachlan KR, Zheng X, Radich J et al..  2015.  Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. The Lancet Haematology. 2(8):e339-e346. Abstract
2014
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR et al..  2014.  NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.. Blood. 124(15):2400-7. Abstract
Advani AS, McDonough S, Coutre S, Wood B, Radich J, Mims M, O'Donnell M, Elkins S, Becker M, Othus M et al..  2014.  SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.. British journal of haematology. Abstract
Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U.  2014.  Systematic Assessment of Decision-Analytic Models for Chronic Myeloid Leukemia.. Applied health economics and health policy. Abstract
Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G et al..  2014.  Medical Decision Analysis for the First-line Therapy of Chronic Myeloid Leukemia.. Leukemia & lymphoma. 55(8):1758-67. Abstract
2013
Bar M, Radich J.  2013.  Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemia.. Journal of the National Comprehensive Cancer Network : JNCCN. 11(3):308-15. Abstract
Rochau U, Sroczynski G, Wolf D, Schmidt S, Jahn B, Conrads-Frank A, Stenehjem D, Brixner D, Radich J, Gastl G et al..  2013.  Uncertainty and Cost-Effectiveness Analysis of the Sequential Application of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia. Value in Health. 16:A409-A409. Abstract
2012
Foss EJ, Radulovic D, Stirewalt DL, Radich J, Sala-Torra O, Pogosova-Agadjanyan EL, Hengel SM, Loeb KR, Deeg HJ, Meshinchi S et al..  2012.  Proteomic Classification of Acute Leukemias by Alignment-Based Quantitation of LC-MS/MS Data Sets.. Journal of proteome research. 11(10):5005-10. Abstract
Cortes J, Radich J, Mauro MJ.  2012.  Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.. Clinical advances in hematology & oncology : H&O. 10(10 Suppl 19):1-16. Abstract